Intra-Cellular Therapies

Intra-Cellular Therapies is developing new drugs for the treatment of neuropsychiatric and neurological disorders, as well as other diseases of the central nervous system (CNS). The company combines the efforts of medicinal chemists, pharmacologists, biologists, and clinical development scientists into a dynamic team, translating world-class research expertise into novel therapeutics. The company’s lead product, ITI-007, is a novel 5-HT2A receptor antagonist and dopamine receptor phosphoprotein modulator (DPPM), designed to address multiple deficits in patients with schizophrenia while lacking the side effects associated with existing antipsychotic medications.